Sutimlimab for Relapsed Cold Agglutinin Disease: Real‐Life Evidence of Sustained Response With Extended‐Interval Dosing | Synapse
March 3, 2026
Sutimlimab for Relapsed Cold Agglutinin Disease: Real‐Life Evidence of Sustained Response With Extended‐Interval Dosing
Key Points
Sustained response was observed in patients with cold agglutinin disease, demonstrating significant clinical implications.
The analysis showed a notable improvement in symptoms with extended-interval dosing of sutimlimab over time.
Assessment using real-life data provided insights into the efficacy of sutimlimab in managing cold agglutinin disease.
Further investigation is warranted to confirm these findings and understand long-term effects of treatment.
Abstract
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.